Vertex Pharmaceuticals is discontinuing development of VX-864. A phase II clinical trial of the drug has reached its primary endpoint, but the drug was not effective enough. The company intends to use the data to develop a more effective drug for alpha-1 antitrypsin deficiency with a similar mechanism of action in 2022.